Plant Name: Glycine max
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TAS2R31; | |
| TSHR; | |
| ADORA3; | |
| BLM; TDP1; PKM; DAO; HSD17B1; AKR1B1; GFER; NOX4; ALOX15; USP2; TNKS; TNKS2; AOX1; | |
| MGAM; ACHE; | |
| CFTR; | |
| GSK3B; KDR; FLT3; ABL1; MAPK1; SYK; EGFR; PIM1; CDK6; AURKB; AURKA; CSNK2A1; | |
| CA2; CA1; CA12; CA9; CA5B; CA4; CA5A; CA3; CA14; CA6; CA7; | |
| AR; | |
| ESR2; ESR1; | |
| NR1H3; | |
| ESRRB; ESRRA; | |
| KDM4E; | |
| MAOA; PTGS2; ALDH2; XDH; | |
| F2; | |
| TP53; NFKB1; HIF1A; | |
| ABCG2; ABCC1; | |
| SLCO1B3; SLCO1B1; | |
| LMNA; RAB9A; NPC1; MAPT; THPO; TTR; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | DAO | D-amino-acid oxidase | P14920 | CHEMBL5485 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 1 group H | NR1H3 | LXR-alpha | Q13133 | CHEMBL2808 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Serine protease | F2 | Thrombin | P00734 | CHEMBL204 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Taste receptor (taste family GPCR) | TAS2R31 | Taste receptor type 2 member 31 | P59538 | CHEMBL2034804 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.644E-12 | 3.571E-09 | ABL1, AURKB, CA2, CA7, CDK6, CFTR, EGFR, F2, HIF1A, KDR, MAPK1, NPC1, NR1H3, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.759E-12 | 7.359E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.764E-11 | 2.407E-08 | ALOX15, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, TBXAS1, XDH |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 4.424E-11 | 3.010E-08 | AR, CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1, NR1H3 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 6.585E-11 | 4.217E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4, PTGS2, TBXAS1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.913E-10 | 9.917E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.822E-10 | 9.917E-08 | AR, BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, NR1H3, TNKS, TP53 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 8.556E-10 | 3.653E-07 | ABL1, AKR1B1, BLM, CDK6, CFTR, CYP1B1, EGFR, KDR, MAPK1, NFKB1, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.126E-09 | 1.215E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.494E-08 | 4.396E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.456E-08 | 6.999E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 5.773E-08 | 1.381E-05 | EGFR, F2, MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.013E-07 | 2.373E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 2.038E-07 | 4.058E-05 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.243E-07 | 4.360E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 4.622E-07 | 8.317E-05 | ACHE, ADORA3, ALOX15, AURKA, CYP1A1, EGFR, F2, TP53 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 4.801E-07 | 8.570E-05 | AURKB, MAPK1, TNKS, TNKS2 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 6.185E-07 | 1.052E-04 | ABCC1, CA2, CA4, CA9, EGFR, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 8.493E-07 | 1.399E-04 | ABL1, AKR1B1, AR, AURKA, AURKB, CSNK2A1, EGFR, GSK3B, HIF1A, KDR, LMNA, NFKB1, PIM1, PTGS2, TP53 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.604E-06 | 3.858E-04 | ABCG2, ACHE, AOX1, BLM, CSNK2A1, EGFR, ESR1, ESR2, FLT3, KDR, MAPK1, MAPT, NFKB1, PKM, PTGS2, RAB9A, TP53, TTR, USP2, XDH |
| BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 3.152E-06 | 4.516E-04 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 3.911E-06 | 5.355E-04 | ABL1, AKR1B1, CYP1B1, EGFR, MAPK1, TP53 |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 4.644E-06 | 6.129E-04 | EGFR, KDR, SYK |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 5.250E-06 | 6.725E-04 | AR, ESR1, ESR2, ESRRA, ESRRB, NR1H3, PIM1 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 6.616E-06 | 8.186E-04 | CA2, CA7, CFTR |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 6.942E-06 | 8.492E-04 | CSNK2A1, HIF1A, KDR, MAPT |
| BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 7.196E-06 | 8.705E-04 | ABL1, AKR1B1, CYP1B1, KDR, NFKB1, TP53 |
| BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 8.900E-06 | 1.059E-03 | AURKB, MAPK1, TNKS, TNKS2 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 9.072E-06 | 1.068E-03 | AR, CYP19A1, ESR1 |
| MF | GO:0005488; binding | GO:0050660; flavin adenine dinucleotide binding | 1.008E-05 | 1.167E-03 | AOX1, DAO, GFER, NOX4, XDH |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.028E-05 | 1.182E-03 | ABCC1, ABCG2, ABL1, AURKA, AURKB, BLM, CDK6, CFTR, CSNK2A1, EGFR, FLT3, GSK3B, KDR, MAPK1, PIM1, PKM, SYK, TP53 |
| BP | GO:0051179; localization | GO:0015850; organic hydroxy compound transport | 1.090E-05 | 1.243E-03 | ABCG2, CFTR, NPC1, SLCO1B1, SLCO1B3, SYK |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.139E-05 | 1.285E-03 | AR, ESR1, ESR2, ESRRA, ESRRB, NR1H3 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.206E-05 | 1.347E-03 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 1.423E-05 | 1.519E-03 | AR, CFTR, ESR1, HIF1A, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 1.488E-05 | 1.557E-03 | AOX1, XDH |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.488E-05 | 1.557E-03 | ESR1, ESR2 |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 1.892E-05 | 1.925E-03 | ADORA3, AR, CYP1B1, ESR1, ESR2, MAPK1, NFKB1, PIM1, SYK |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 2.142E-05 | 2.110E-03 | ABCG2, ACHE, AOX1, AR, AURKA, BLM, DAO, EGFR, FLT3, HIF1A, MAPT, NFKB1, PTGS2, TP53, TTR, XDH |
| BP | GO:0032501; multicellular organismal process | GO:0045780; positive regulation of bone resorption | 2.474E-05 | 2.373E-03 | CA2, EGFR, SYK |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 2.530E-05 | 2.395E-03 | AKR1B1, ALDH2, AOX1, XDH |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 3.295E-05 | 3.027E-03 | ABL1, EGFR, KDR, SYK |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 3.636E-05 | 3.272E-03 | ABL1, ADORA3, AURKA, AURKB, CSNK2A1, CYP1B1, ESR1, GSK3B, MAPT, NFKB1, PIM1, PTGS2, RAB9A, TNKS, TP53 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 3.694E-05 | 3.287E-03 | AR, ESR1, ESR2, ESRRA, ESRRB, NR1H3 |
| BP | GO:0009987; cellular process | GO:0014066; regulation of phosphatidylinositol 3-kinase signaling | 3.762E-05 | 3.330E-03 | EGFR, F2, FLT3, KDR, MAPK1 |
| BP | GO:0008152; metabolic process | GO:1901617; organic hydroxy compound biosynthetic process | 3.960E-05 | 3.450E-03 | AKR1B1, ALOX15, CFTR, CYP19A1, CYP3A4, DAO |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 3.982E-05 | 3.455E-03 | ABL1, CDK6, EGFR, GSK3B, HIF1A, MAPK1, MAPT, PTGS2, SYK, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0032928; regulation of superoxide anion generation | 4.399E-05 | 3.672E-03 | EGFR, MAPT, SYK |
| BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 4.452E-05 | 3.672E-03 | ABL1, HIF1A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.452E-05 | 3.672E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 4.452E-05 | 3.672E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.452E-05 | 3.672E-03 | CYP1A1, CYP3A4 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 4.911E-05 | 3.931E-03 | CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, EGFR, NOX4, PTGS2, RAB9A, TBXAS1 |
| BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 4.964E-05 | 3.959E-03 | AKR1B1, ALOX15, CFTR, CYP19A1, CYP1A1, CYP3A4, PKM, PTGS2, SYK |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 6.112E-05 | 4.703E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0051179; localization | GO:0034502; protein localization to chromosome | 8.116E-05 | 5.930E-03 | AURKB, ESR1, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 8.881E-05 | 6.361E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.881E-05 | 6.361E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 8.881E-05 | 6.361E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.416E-05 | 6.595E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0006066; alcohol metabolic process | 9.763E-05 | 6.770E-03 | AKR1B1, ALDH2, CFTR, CYP1B1, CYP3A4, NPC1, TTR |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.170E-04 | 7.865E-03 | ABL1, ALOX15, EGFR, KDR, NOX4, THPO |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 1.212E-04 | 8.118E-03 | CYP1A2, EGFR, ESR1, ESRRA, PTGS2 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.335E-04 | 8.837E-03 | AKR1B1, HIF1A, MAPK1, MAPT |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.371E-04 | 8.977E-03 | CYP19A1, CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.476E-04 | 9.373E-03 | CYP1A1, CYP3A4 |
| CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 1.476E-04 | 9.373E-03 | AURKA, AURKB |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 1.538E-04 | 9.706E-03 | CYP1B1, HIF1A, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 1.574E-04 | 9.907E-03 | AKR1B1, GSK3B, NFKB1, PKM, TP53, TSHR |
| BP | GO:0050896; response to stimulus | GO:0048585; negative regulation of response to stimulus | 1.584E-04 | 9.914E-03 | ABL1, ALOX15, AR, CDK6, CYP19A1, EGFR, ESR1, ESR2, F2, GSK3B, HIF1A, LMNA, NFKB1, NR1H3, PTGS2, XDH |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 1.583E-04 | 9.914E-03 | BLM, GSK3B, HIF1A, TP53 |
| BP | GO:0009987; cellular process | GO:0045930; negative regulation of mitotic cell cycle | 1.602E-04 | 9.997E-03 | ABL1, AURKA, AURKB, BLM, EGFR, TNKS, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.893E-24 | 4.122E-20 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.912E-20 | 6.469E-16 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.787E-17 | 4.262E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 8.099E-15 | 1.603E-11 | ABL1, AURKB, CA2, CA7, CFTR, EGFR, F2, HIF1A, MAPK1, NPC1, NR1H3, PTGS2, SYK, TNKS, TNKS2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.164E-23 | 2.154E-21 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 7.868E-09 | 7.278E-07 | ALDH2; MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.575E-07 | 4.955E-06 | AR; GSK3B; CDK6; FLT3; ABL1; MAPK1; PTGS2; HIF1A; TP53; EGFR; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.379E-08 | 1.467E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.586E-07 | 4.889E-06 | ABCC1; CDK6; PIM1; ABL1; CYP1B1; MAPK1; PTGS2; TP53; EGFR; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.866E-08 | 2.911E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.889E-07 | 4.955E-06 | PKM; FLT3; MAPK1; TP53; HIF1A; EGFR |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.208E-07 | 8.758E-06 | MGAM; MAOA; ALOX15; AKR1B1; PTGS2; CYP2C19; CYP3A4; CYP19A1; CYP2C9; PKM; DAO; ALDH2; HSD17B1; TBXAS1; CYP1A2; CYP1A1; AOX1; XDH |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.169E-08 | 2.911E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.255E-07 | 4.955E-06 | CYP2C9; MAOA; CYP1A2; AOX1; CYP3A4; CYP2C19 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.030E-06 | 1.589E-05 | GSK3B; AR; MAPK1; TP53; EGFR; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.678E-07 | 4.955E-06 | SLCO1B1; CA2; SLCO1B3; CYP3A4; CFTR; ABCG2 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.203E-06 | 1.712E-05 | HSD17B1; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.963E-06 | 4.888E-05 | CYP2C9; MAOA; ALOX15; MAPK1; CYP2C19; PTGS2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.548E-06 | 4.689E-05 | CYP2C9; ALOX15; TBXAS1; CYP2C19; PTGS2 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.844E-06 | 5.271E-05 | CDK6; MAPK1; TP53; EGFR; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 7.452E-06 | 7.378E-05 | GSK3B; MAPK1; ESR1; NFKB1; ESR2 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.490E-06 | 5.191E-05 | CYP2C9; CYP1A2; CYP1A1; AOX1; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 7.976E-06 | 7.378E-05 | CDK6; ABL1; MAPK1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.068E-05 | 9.404E-05 | GSK3B; NR1H3; MAPK1; TP53; EGFR; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.110E-05 | 3.306E-04 | GSK3B; CDK6; SYK; KDR; MAPK1; TP53; EGFR; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.213E-05 | 1.020E-04 | GSK3B; CDK6; CSNK2A1; RAB9A; TP53; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.976E-06 | 7.378E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.142E-04 | 6.817E-04 | KDR; MAPK1; TP53; HIF1A; ESR1; EGFR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 8.151E-05 | 5.585E-04 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 8.826E-05 | 5.631E-04 | GSK3B; ABL1; MAPK1; TP53; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.205E-04 | 6.968E-04 | CDK6; PKM; SYK; MAPK1; TP53; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 5.779E-05 | 4.276E-04 | CDK6; MAPK1; TP53; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 4.308E-05 | 3.321E-04 | GSK3B; MAPK1; TP53; EGFR |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 8.826E-05 | 5.631E-04 | ABCC1; ADORA3; MAPK1; TP53; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.198E-05 | 4.410E-04 | FLT3; PIM1; MAPK1; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.038E-04 | 6.404E-04 | CDK6; MAPK1; TP53; EGFR |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.632E-04 | 8.627E-04 | GSK3B; SYK; MAPK1; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.465E-04 | 7.973E-04 | CDK6; MAPK1; TP53; EGFR |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 3.208E-04 | 1.604E-03 | GSK3B; ABL1; MAPK1; EGFR |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.069E-04 | 1.577E-03 | CDK6; PTGS2; TP53; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 5.245E-04 | 2.426E-03 | MAPK1; ESR1; EGFR; ESR2 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 9.735E-04 | 4.093E-03 | GSK3B; SYK; CSNK2A1; TP53; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 4.138E-04 | 2.014E-03 | SYK; CSNK2A1; PTGS2; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 6.091E-04 | 2.683E-03 | MAPK1; HIF1A; EGFR; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.632E-03 | 6.299E-03 | KDR; ABL1; MAPK1; EGFR; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.903E-03 | 7.040E-03 | LMNA; MAPK1; TP53; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.218E-03 | 5.008E-03 | GSK3B; CDK6; ABL1; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.217E-03 | 8.042E-03 | CDK6; MAPK1; TP53; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.706E-03 | 9.293E-03 | MAPK1; MAPT; TP53; EGFR; NFKB1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.559E-03 | 6.271E-03 | KDR; MAPK1; PTGS2 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 6.669E-03 | 1.990E-02 | MAPK1; CFTR; NFKB1; TSHR |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 7.024E-03 | 2.033E-02 | GSK3B; KDR; MAPK1; EGFR |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 6.488E-03 | 1.968E-02 | PIM1; MAPK1; NFKB1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 6.488E-03 | 1.968E-02 | MAPK1; HIF1A; EGFR |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.609E-03 | 9.284E-03 | MAPK1; PTGS2; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.634E-03 | 6.299E-03 | GSK3B; MAPK1; TP53 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 7.033E-03 | 2.033E-02 | GSK3B; MAPK1; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 8.001E-03 | 2.223E-02 | GSK3B; NR1H3; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 8.203E-03 | 2.232E-02 | MAPK1; PTGS2; NFKB1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.712E-03 | 9.293E-03 | CSNK2A1; MAPK1; EGFR |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.087E-02 | 2.832E-02 | SYK; TBXAS1; MAPK1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.872E-03 | 7.040E-03 | ABL1; MAPK1; NFKB1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.111E-02 | 2.855E-02 | AR; MAPK1; AURKA |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.343E-02 | 3.313E-02 | SYK; MAPK1; NFKB1 |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 8.746E-04 | 3.763E-03 | DAO; ALDH2; MAOA |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.873E-04 | 2.312E-03 | MAPK1; TP53; EGFR |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.758E-02 | 3.966E-02 | THPO; FLT3; KDR; EGFR |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.211E-02 | 3.069E-02 | GSK3B; ABL1; MAPK1 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.631E-02 | 3.772E-02 | GSK3B; CSNK2A1; TP53 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.693E-02 | 3.866E-02 | SYK; MAPK1; EGFR |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.631E-02 | 3.772E-02 | GSK3B; ESRRB; MAPK1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.918E-02 | 4.170E-02 | GSK3B; NR1H3; NFKB1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 2.159E-02 | 4.437E-02 | MAPK1; PTGS2; EGFR |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 2.159E-02 | 4.437E-02 | THPO; PIM1; AOX1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 6.006E-04 | 2.683E-03 | ABCC1; CFTR; ABCG2 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.135E-02 | 4.437E-02 | MAPK1; HIF1A |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.875E-02 | 4.130E-02 | PTGS2; TSHR |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 2.068E-02 | 4.398E-02 | ALDH2; AKR1B1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.939E-02 | 4.170E-02 | MAPK1; NFKB1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.813E-02 | 4.040E-02 | GSK3B; TP53 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.400E-02 | 3.364E-02 | PKM; MAPK1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.456E-02 | 3.454E-02 | MAOA; NFKB1 |
| hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 1.400E-02 | 3.364E-02 | ALDH2; AOX1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.291E-02 | 3.227E-02 | CYP3A4; XDH |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 5.276E-03 | 1.683E-02 | MAPK1; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.639E-03 | 1.768E-02 | MGAM; AKR1B1 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 4.583E-03 | 1.488E-02 | MAPK1; EGFR |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 9.871E-03 | 2.609E-02 | PKM; ALDH2 |
| hsa00260 | Glycine, serine and threonine metabolism_Homo sapiens_hsa00260 | 9.871E-03 | 2.609E-02 | DAO; MAOA |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 7.621E-03 | 2.169E-02 | MAOA; AOX1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 8.050E-03 | 2.223E-02 | ALDH2; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.336E-03 | 1.122E-02 | CA2; CA4 |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 3.630E-03 | 1.199E-02 | ALDH2; MAOA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.377E-04 | 7.722E-04 | CYP1A2; XDH |
| hsa00750 | Vitamin B6 metabolism_Homo sapiens_hsa00750 | 2.229E-02 | 4.532E-02 | AOX1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1; F2 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ALDH2 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | AURKA |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; EGFR; EGFR; KDR |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; F2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; PTGS2; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; KDR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; GSK3B; ACHE; ACHE; ACHE; MAOA; MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; AKR1B1; MGAM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; FLT3; EGFR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS2; PTGS2; PTGS2; PTGS2; AR; ACHE; ESR1; PKM |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; KDR |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR; KDR; KDR; KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; ABL1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | F2 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; EGFR; EGFR; KDR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR; KDR; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1; ESRRA |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1; F2 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; TBXAS1; SYK; SYK; ESRRA |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; SYK |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; EGFR; ALDH2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | F2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | F2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; SYK |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; DAO; MAPT |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
| I00-I99: Diseases of the circulatory system | Stroke in atrial fibrillation | I48, I61-I63 | F2 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; SYK |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1; F2 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1; F2; F2; SYK |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3; CA9; EGFR; EGFR; EGFR; ESR1; ESR1; KDR; KDR; KDR; CYP19A1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood forming organ disorders | D75.9 | F2 |
| A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; EGFR; CYP19A1 |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F2 |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F2 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; F2; MGAM; KDR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; PTGS2; PTGS2; PTGS2; AKR1B1; SYK; ESRRA |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; AR; GSK3B; HIF1A; PIM1; ADORA3; TP53; MAPK1; CA1; FLT3; FLT3; CA9; ABL1; NFKB1; ACHE; EGFR; ESR1; ESR1; F2; KDR; CSNK2A1; AURKA; SYK |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F2 |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F2 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; ABCC1; ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR; KDR; KDR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; EGFR |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AURKB; HIF1A; TP53; MAPK1; FLT3; CA9; ABL1; EGFR; F2; KDR; KDR; KDR; PKM; AURKA; SYK |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; NFKB1; TBXAS1; MGAM |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; TP53; TP53; FLT3; FLT3; AURKA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; ADORA3 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR; AKR1B1; KDR; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ABL1; ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; AURKA |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | F2; F2 |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ABL1; EGFR; ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| NA: NA | Nonvalvular atrial fibrillation | NA | F2 |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; ABL1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR; KDR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; CA1; CA1; ACHE; AKR1B1 |
| NA: NA | GIST | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; XDH; AKR1B1; ABCC1; ABCC1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; TBXAS1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; SYK |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |